Sutro Biopharma, Inc.

After last week, the main U.S. small-cap index has now posted three straight weeks of gains as investors’ risk appetite continues to grow. Earnings season is in full swing: More than 200 companies reported results last week, and aggregate earnings per share are down. Below we recap what happened in the small-cap space during the week of April 21-25 and what to expect in the week ahead.

Small-cap recap/preview: 147% gain for biotech, risk appetite up, earnings down

Intensity Therapeutics, Inc.

Quotes on Intensity Therapeutics, a biotech startup focused on developing new cancer treatments, <a href="https://finance.yahoo.com/quote/INTS/">fell</a> almost 30% yesterday, April 23, after the company revealed plans to raise $8 million through a public offering, which is set to dilute shareholders.

Biotech startup Intensity sinks 30% after stock offering announced


Peloton Interactive, Inc.

Quotes on Peloton Interactive, a maker of fitness equipment and media content, <a href="https://finance.yahoo.com/quote/PTON/">gained</a> 8% yesterday, April 22, after Wall Street veteran Stephen Guilfoyle <a href="https://pro.thestreet.com/trade-ideas/new-peloton-price-target-panic-point-as-wall-street-braces-for-contraction#viaLogin">claimed</a> that the company’s balance sheet “is not nearly as weak as many may believe.”

Peloton soars on analysis from veteran Wall Street trader 


CaliberCos Inc.

Quotes on CaliberCos Inc., which invests in real estate, <a href="https://finance.yahoo.com/quote/CWD/">plummeted</a> more than 33% yesterday, April 17, before paring some of the losses in after-hours trading. The plunge was triggered by the announced terms of a $900,000 stock offering, which was priced at a steep discount, signaling an urgent need for capital and potential dilution for existing shareholders.

Real estate investor CaliberCos loses third of market value after public offering

MIRA Pharmaceuticals, Inc.

Quotes on MIRA Pharmaceuticals, a developer of treatments for neurological and neuropsychiatric disorders, <a href="https://finance.yahoo.com/quote/MIRA/">jumped</a> almost 20% yesterday, April 16, before giving back some of the gains in after-hours trading. The surge came after the company reported positive animal trial results of its drug candidate for diabetic neuropathy, a condition in which nerves are damaged due to high blood sugar levels.

MIRA Pharmaceuticals jumps 20% on successful trial of ketamine analog


Lisata Therapeutics, Inc.

Novo Nordisk A/S

Quotes on Lisata Therapeutics, a pharmaceutical company developing therapies to combat tumors, <a href="https://finance.yahoo.com/quote/LSTA/">gained</a> more than 10% yesterday, April 15, after it announced a partnership with one of the largest industry manufacturers, Catalent, to evaluate the efficacy of a promising Lisata therapy. Since December, Catalent has been owned by Novo Holdings, the controlling shareholder of Denmark’s Novo Nordisk, a global leader in weight-loss medications.

Biotech small cap Lisata Therapeutics jumps 10% on partnership with Novo subsidiary


Verve Therapeutics, Inc.

Shares of Verve Therapeutics, a biotech small cap specializing in gene-editing medicines to treat cardiovascular disease, <a href="https://finance.yahoo.com/quote/VERV/">surged</a> more than 26% yesterday, April 14, after the company reported positive early trial results for its therapy for high cholesterol.

Verve Therapeutics reports good early test results for cholesterol drug, shares soar

Last week, small caps were the worst-performing segment of the U.S. market, while volatility reached staggering levels — 3.5 times the five-year average. Here's a recap of what happened in the space between April 7 and April 11, and what to expect in the week ahead.

Small-cap recap/preview: Underperformance, extreme volatility, 30 firms to report

Satixfy Communications Ltd.

Futures on the small-cap Russell 2000 are down nearly 4% today, April 7. Last week, the index officially entered a bear market as it is now down 25% versus its high from November. This week, investors are bracing for more news on U.S. tariffs.

Anastasia Skrynnikova

Writes about: